on May 25, 2006
Published online before print May 25, 2006, doi: 10.1161/01.ATV.0000229243.49320.c9
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on January 13, 2006
Accepted on May 10, 2006
Angiogenic Murine Endothelial Progenitor Cells Are Derived From a Myeloid Bone Marrow Fraction and Can Be Identified by Endothelial NO Synthase Expression
C. J.M. Loomans ;
From the Departments of Immunology (C.J.M.L., H.W., P.J.M.L., H.A.D., F.J.T.S.), Cell Biology and Genetics (R.d., R.v.), and Vascular Surgery (R.d.), Erasmus Medical Center, Rotterdam, the Netherlands; and Department of Nephrology (C.J.M.L., H.C.d., T.J.R., A.J.v.), University Medical Center, Leiden, the Netherlands.
* To whom correspondence should be addressed. E-mail: f.staal{at}erasmusmc.nl.
Objective--Endothelial progenitor cells (EPCs) contribute to postnatal neovascularization and are therefore of great interest for autologous cell therapies to treat ischemic vascular disease. However, the origin and functional properties of these EPCs are still in debate.
Methods and Results--Here, ex vivo expanded murine EPCs were characterized in terms of phenotype, lineage potential, differentiation from bone marrow (BM) precursors, and their functional properties using endothelial NO synthase (eNOS)-green fluorescent protein transgenic mice. Despite high phenotypic overlap with macrophages and dendritic cells, EPCs displayed unique eNOS expression, endothelial lineage potential in colony assays, and angiogenic characteristics, but also immunologic properties such as interleukin-12p70 production and low levels of T-cell stimulation. The majority of EPCs developed from an immature, CD31+Ly6C+ myeloid progenitor fraction in the BM. Addition of myeloid growth factors such as M-colony-stimulating factor (CSF) and GM-CSF stimulated the expansion of spleen-derived EPCs but not BM-derived EPCs.
Conclusion--The close relationship between EPCs and other myeloid lineages may add to the complexity of using them in cell therapy. Our mouse model could be a highly useful tool to characterize EPCs functionally and phenotypically, to explore the origin and optimize the isolation of EPC fractions for therapeutic neovascularization.
Key words: endothelial progenitor cells • myeloid cells • neovascularization • lineage differentiation • eNOS
This article has been cited by other articles:
 |
|
 |
|
  D. P Sieveking and M. K. Ng Cell therapies for therapeutic angiogenesis: back to the bench Vascular Medicine, May 1, 2009; 14(2): 153 - 166. [Abstract] [PDF]
|
|
|
|
 |
|
 J.-L. Balligand, O. Feron, and C. Dessy eNOS Activation by Physical Forces: From Short-Term Regulation of Contraction to Chronic Remodeling of Cardiovascular Tissues Physiol Rev, April 1, 2009; 89(2): 481 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Bonder, W. Y. Sun, T. Matthews, C. Cassano, X. Li, H. S. Ramshaw, S. M. Pitson, A. F. Lopez, P. T. Coates, R. L. Proia, et al. Sphingosine kinase regulates the rate of endothelial progenitor cell differentiation Blood, February 26, 2009; 113(9): 2108 - 2117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Hirschi, D. A. Ingram, and M. C. Yoder Assessing Identity, Phenotype, and Fate of Endothelial Progenitor Cells Arterioscler Thromb Vasc Biol, September 1, 2008; 28(9): 1584 - 1595. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sugiura, T. Kondo, Y. Kureishi-Bando, Y. Numaguchi, O. Yoshida, Y. Dohi, G. Kimura, R. Ueda, T. J. Rabelink, and T. Murohara Nifedipine Improves Endothelial Function: Role of Endothelial Progenitor Cells Hypertension, September 1, 2008; 52(3): 491 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Sieveking, A. Buckle, D. S. Celermajer, and M. K.C. Ng Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J. Am. Coll. Cardiol., February 12, 2008; 51(6): 660 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Rookmaaker, M. C. Verhaar, H. C. de Boer, R. Goldschmeding, J. A. Joles, H. A. Koomans, H.-J. Grone, and T. J. Rabelink Met-RANTES reduces endothelial progenitor cell homing to activated (glomerular) endothelium in vitro and in vivo Am J Physiol Renal Physiol, August 1, 2007; 293(2): F624 - F630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Sorrentino, F. H. Bahlmann, C. Besler, M. Muller, S. Schulz, N. Kirchhoff, C. Doerries, T. Horvath, A. Limbourg, F. Limbourg, et al. Oxidant Stress Impairs In Vivo Reendothelialization Capacity of Endothelial Progenitor Cells From Patients With Type 2 Diabetes Mellitus: Restoration by the Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Rosiglitazone Circulation, July 10, 2007; 116(2): 163 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Deanfield, J. P. Halcox, and T. J. Rabelink Endothelial Function and Dysfunction: Testing and Clinical Relevance Circulation, March 13, 2007; 115(10): 1285 - 1295. [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Schatteman, M. Dunnwald, and C. Jiao Biology of bone marrow-derived endothelial cell precursors Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H1 - H18. [Abstract] [Full Text] [PDF]
|
|